Cancer Genetics

NASDAQ

- -

- -

- -

- -

- -

- -

Cancer Genetics, Inc., through its subsidiary, vivoPharm, Pty Ltd., provides contract research services primarily focusing on studies to guide drug discovery and development programs in the oncology and immuno-oncology fields. The company's clinical offerings include a portfolio of proprietary tests, such as comparative genomic hybridization microarrays and next generation sequencing panels, gene expression tests, and DNA fluorescent in situ hybridization probes targeting hematological, and human papillomavirus-associated cancers, which include cervical, anal, head, and neck cancers. It serves the biotechnology and pharmaceutical customers in the United States, Europe, and Australia. Cancer Genetics, Inc. was founded in 1999 and is headquartered in Rutherford, New Jersey.